Society for Translational Oncology navigateright Episode
Daniel Haber, MD, PhD,
Massachusetts General Hospital
We will present initial proof of concept applications of a CTC-Score analysis for early detection of hepatocellular cancer among patients with underlying chronic liver disease, stratification of metastatic prostate cancer patients with poor response to anti-androgen therapy, demonstration of early response of melanoma patients to immune checkpoint inhibitors, and monitoring drug-induced changes in estrogen signaling in women with advanced breast cancer. Together, these analyses highlight potential clinical applications of RNA-based liquid biopsy measurements in the care of patients with cancer.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.